Clinical Trial Update: Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

This clinical trial update indicates the Phase 2 study of sorafenib tosylate plus gemcitabine hydrochloride in recurrent ovarian epithelial cancer and recurrent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED